Related Experiment Video
Updated: Jun 29, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic adenoviruses and immunopeptidomics: a convenient marriage
Marc Garcia-Moure1, Andrew G Gillard1, Marta M Alonso2,3
1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Oncolytic viruses (OVs) are biological therapeutic agents that selectively destroy cancer cells while sparing normal healthy cells. Besides direct oncolysis, OV infection induces a proinflammatory shift in the tumor microenvironment and the release of tumor-associated antigens (TAAs) that might induce an anti-tumor immunity. Due to their immunostimulatory effect, OVs have been explored for cancer vaccination against specific TAAs. However, this approach usually requires genetic modification of the virus and the production of a new viral vector for each target, which is difficult to implement for low prevalent antigens. In a recent study, Chiaro et al. presented an elegant proof of concept on how to implement the PeptiCRAd vaccination platform to overcome this limitation for the treatment of mesothelioma. Authors showed the feasibility of identifying immunogenic TAAs in human mesothelioma and using them to coat oncolytic adenovirus particles. The result was a customized virus-based cancer vaccine that circumvents time and resource-consuming steps incurred from genetically engineering viruses. Although some questions remain to be addressed, this interesting approach suggests novel strategies for personalized cancer medicine using oncolytic virotherapy.
Insights
Oncolytic viruses (OVs) offer a novel approach to cancer treatment by selectively destroying tumor cells and stimulating anti-tumor immunity. A new platform coats OVs with tumor antigens, creating personalized vaccines for mesothelioma without genetic engineering.
Area of Science:
- Oncolytic virotherapy
- Cancer immunology
- Vaccine development
Background:
- Oncolytic viruses (OVs) selectively target and destroy cancer cells.
- OV infection can stimulate anti-tumor immunity by releasing tumor-associated antigens (TAAs).
- Current OV vaccination strategies often require genetic modification for each target antigen, limiting application for rare antigens.
Purpose of the Study:
- To present a proof-of-concept for the PeptiCRAd vaccination platform for mesothelioma treatment.
- To demonstrate a method for creating customized virus-based cancer vaccines without genetic engineering.
- To overcome limitations in developing OV-based vaccines for low-prevalent antigens.
Main Methods:
- Identification of immunogenic TAAs in human mesothelioma.
- Coating oncolytic adenovirus particles with identified TAAs.
- Utilizing the PeptiCRAd platform for vaccine development.
Main Results:
- Demonstrated the feasibility of the PeptiCRAd platform for mesothelioma.
- Successfully created customized virus-based cancer vaccines.
- Circumvented time-consuming genetic engineering steps for viral vector production.
Conclusions:
- The PeptiCRAd platform offers an efficient strategy for developing personalized cancer vaccines.
- This approach suggests novel avenues for personalized cancer medicine using oncolytic virotherapy.
- Further research is needed to address remaining questions and optimize the strategy.
More Related Videos
08:51Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
